508 related articles for article (PubMed ID: 15658851)
1. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biochemical characterization of a series of 17α-perfluoroalkylated estradiols as selective ligands for estrogen receptor α.
Eignerová B; Sedlák D; Dracínský M; Bartunek P; Kotora M
J Med Chem; 2010 Oct; 53(19):6947-53. PubMed ID: 20812681
[TBL] [Abstract][Full Text] [Related]
5. New scaffolds for the design of selective estrogen receptor modulators.
Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
[TBL] [Abstract][Full Text] [Related]
6. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Busch S; Gust R
J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor ligands. Part 6: Synthesis and binding affinity of dihydrobenzodithiins.
Tan Q; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 Jul; 14(14):3753-5. PubMed ID: 15203156
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
[TBL] [Abstract][Full Text] [Related]
9. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
[TBL] [Abstract][Full Text] [Related]
10. Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells.
Bourgoin-Voillard S; Gallo D; Laïos I; Cleeren A; Bali LE; Jacquot Y; Nonclercq D; Laurent G; Tabet JC; Leclercq G
Biochem Pharmacol; 2010 Mar; 79(5):746-57. PubMed ID: 19879249
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.
Chesworth R; Zawistoski MP; Lefker BA; Cameron KO; Day RF; Mangano FM; Rosati RL; Colella S; Petersen DN; Brault A; Lu B; Pan LC; Perry P; Ng O; Castleberry TA; Owen TA; Brown TA; Thompson DD; DaSilva-Jardine P
Bioorg Med Chem Lett; 2004 Jun; 14(11):2729-33. PubMed ID: 15125923
[TBL] [Abstract][Full Text] [Related]
12. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA
J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity.
Compton DR; Sheng S; Carlson KE; Rebacz NA; Lee IY; Katzenellenbogen BS; Katzenellenbogen JA
J Med Chem; 2004 Nov; 47(24):5872-93. PubMed ID: 15537344
[TBL] [Abstract][Full Text] [Related]
15. Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
Yang C; Xu G; Li J; Wu X; Liu B; Yan X; Wang M; Xie Y
Bioorg Med Chem Lett; 2005 Mar; 15(5):1505-7. PubMed ID: 15713417
[TBL] [Abstract][Full Text] [Related]
16. Benzothiophene and naphthalene derived constrained SERMs.
Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Malamas MS; Manas ES; McDevitt RE; Gunawan I; Xu ZB; Collini MD; Miller CP; Dinh T; Henderson RA; Keith JC; Harris HA
J Med Chem; 2004 Oct; 47(21):5021-40. PubMed ID: 15456246
[TBL] [Abstract][Full Text] [Related]
18. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z
J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes.
Meyers MJ; Sun J; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA
J Med Chem; 1999 Jul; 42(13):2456-68. PubMed ID: 10395487
[TBL] [Abstract][Full Text] [Related]
20. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
Mukherjee S; Saha A; Roy K
Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
